《新股消息》朝聚眼科(02219.HK)公開超購近113倍及上限定價 一手中籤率5.67%
眼科醫療服務集團朝聚眼科(02219.HK)公佈招股結果,發售約1.71億股,當中3,343萬股爲舊股。原計劃發售股份中,90%爲國際配售,10%公開發售。公開發售錄超購112.97倍,經重新分配後,公開發售股數增至50%;認購一手500股中籤率爲5.67%,認購18手纔可穩獲一手。
每股發售價定於10.6元,爲上限定價(招股價介乎9.48元至10.6元),該股將於明日(7日)掛牌,海通國際及華泰金融控股(香港)爲聯席保薦人。
基石投資者包括富國基金、Gigantic Wealth、The Valliance Fund及通柏資本(香港),合共認購7,467.45萬股股份,佔緊隨全球發售完成後公司已發行股本約10.86%。公司估計,集資淨額爲13.57億元,約35.8%用於設立新醫院、搬遷及升級醫院;44.8%用於收購醫院;9.4%升級信息技術系統;餘下10%作營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.